Role of oxidative stress in oxaliplatin‐induced enteric neuropathy and colonic dysmotility in mice

• Published in: British journal of pharmacology 2016-12, Vol.173 (24), p.3502-3521
• Main Authors: McQuade, Rachel M, Carbone, Simona E, Stojanovska, Vanesa, Rahman, Ahmed, Gwynne, Rachel M, Robinson, Ainsley M, Goodman, Craig A, Bornstein, Joel C, Nurgali, Kulmira
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacology; Apoptosis; Arginine; Colon; Colon - drug effects; Colon - metabolism; Colon - pathology; Colorectal carcinoma; Constipation; Cytochrome c; Electrophysiology; Enteric nervous system; Ganglia; Immunohistochemistry; Intestinal Pseudo-Obstruction - chemically induced; Intestinal Pseudo-Obstruction - pathology; Male; Membrane Potential, Mitochondrial - drug effects; Mice; Mice, Inbred BALB C; Mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; Muscles; Myenteric plexus; Neuromuscular junctions; Neuromuscular transmission; Neuropathy; Nitration; Nitric-oxide synthase; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - pharmacology; Oxaliplatin; Oxidative stress; Oxidative Stress - drug effects; Platinum; Proteins; Reactive oxygen species; Research Paper; Research Papers; Rodents; Sodium; Sodium nitroprusside; Superoxides - metabolism; Transducers; Water content
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/bph.13646

Background and Purpose Oxaliplatin is a platinum‐based chemotherapeutic drug used as a first‐line therapy for colorectal cancer. However, its use is associated with severe gastrointestinal side‐effects resulting in dose limitations and/or cessation of treatment. In this study, we tested whether oxidative stress, caused by chronic oxaliplatin treatment, induces enteric neuronal damage and colonic dysmotility. Experimental Approach Oxaliplatin (3 mg·kg−1 per day) was administered in vivo to Balb/c mice intraperitoneally three times a week. The distal colon was collected at day 14 of treatment. Immunohistochemistry was performed in wholemount preparations of submucosal and myenteric ganglia. Neuromuscular transmission was studied by intracellular electrophysiology. Circular muscle tone was studied by force transducers. Colon propulsive activity studied in organ bath experiments and faeces were collected to measure water content. Key Results Chronic in vivo oxaliplatin treatment resulted in increased formation of reactive oxygen species (O2ˉ), nitration of proteins, mitochondrial membrane depolarisation resulting in the release of cytochrome c, loss of neurons, increased inducible NOS expression and apoptosis in both the submucosal and myenteric plexuses of the colon. Oxaliplatin treatment enhanced NO‐mediated inhibitory junction potentials and altered the response of circular muscles to the NO donor, sodium nitroprusside. It also reduced the frequency of colonic migrating motor complexes and decreased circular muscle tone, effects reversed by the NO synthase inhibitor, Nω‐Nitro‐L‐arginine. Conclusion and Implications Our study is the first to provide evidence that oxidative stress is a key player in enteric neuropathy and colonic dysmotility leading to symptoms of chronic constipation observed in oxaliplatin‐treated mice.